Company intelligence / Profile preview

New Amsterdam Sciences, Inc.

Scottsdale, Arizona, United Statesnasciences.com ↗
Ownership
Private
Employees
~10
Development stage
Other
01

Overview

New Amsterdam Sciences is a clinical-stage bioscience company developing small molecule antioxidant SOD mimetics and peptide analogues of Substance P for indications including idiopathic pulmonary fibrosis, influenza, radiation exposure, progressive supranuclear palsy, and epilepsy. The company’s lead programs are in early clinical or preclinical development.

Therapeutic areas
NeurologyInfectious Diseases
Modalities
Small moleculesPeptide analogues
Industry
Biotech
02

Drug pipeline

3 assets

NAS150

Unknown

2 more assets in the full pipeline.

Beyond the preview

Go deeper on New Amsterdam Sciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Amsterdam Sciences, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call